Lexaria Bioscience通过为业务提供资金的股票筹资筹集了4M美元,股票价格为1.50美元,许可证价格为1.37美元。 Lexaria Bioscience raised $4M via a stock offering to fund operations, with shares priced at $1.50 and warrants at $1.37.

Lexaria生物科学公司(LEXX:NASDAQ)宣布,根据Nasdaq规则,在市场上以每股1.50美元的价格直接提供2 666 667股的注册直接销售额400万美元,预期在2025年9月29日左右关闭,但须视习惯条件而定。 Lexaria Bioscience Corp. (LEXX:NASDAQ) announced a $4.0 million registered direct offering of 2,666,667 shares at $1.50 per share, priced at-the-market under Nasdaq rules, with closing expected around September 29, 2025, subject to customary conditions. 同时私募包括未注册的认股权证，以每股 1.37 美元的价格购买最多相同数量的股票，可立即行使并在五年后到期。 A concurrent private placement includes unregistered warrants to purchase up to the same number of shares at $1.37 per share, exercisable immediately and expiring in five years. 支出前的收益预计约为400万美元,用于周转资金和一般公司用途。 Proceeds, before expenses, are expected to be about $4.0 million for working capital and general corporate purposes. 自2025年1月30日起,这项提议在表格S-3的储存登记表下提交。 The offering is under a shelf registration statement on Form S-3, effective January 30, 2025. 该公司的DehidaTECHTM平台旨在改善口服药物供应,包括跨越血脑屏障的口服药物供应,它拥有全球50个被授予专利的专利和更多待批申请。 The company’s DehydraTECH™ platform aims to improve oral drug delivery, including across the blood-brain barrier, and it holds 50 granted patents and additional pending applications globally. 前瞻性声明涉及风险和不确定性。 Forward-looking statements involve risks and uncertainties.